Targeting p53 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance

Melanoma is the deadliest form of skin cancer, primarily due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may predict promising outcomes for p53 activators in melanoma therapy. Herei...

Full description

Bibliographic Details
Main Author: Loureiro, Joana B. (author)
Other Authors: Raimundo, Liliana (author), Calheiros, Juliana (author), Carvalho, Carla (author), Barcherini, Valentina (author), Lima, Nuno R. (author), Gomes, Célia (author), Almeida, Maria Inês (author), Alves, Marco G. (author), Costa, José Luís (author), Santos, Maria M. M. (author), Saraiva, Lucília (author)
Format: article
Language:eng
Published: 2021
Subjects:
Melanoma
Metastasis
Drug resistance
Targeted therapy
p53
Tryptophanol-derived oxazoloisoindolinone
Online Access:http://hdl.handle.net/1822/73358
Country:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/73358

Internet

http://hdl.handle.net/1822/73358

Similar Items